LH stock sentiment todayLabcorp Holdings Inc.
Sentiment verdict
Gossip first, financials second — NEUTRAL at 78% confidence.
Last updated · cached analysis, refreshes periodically
LH
Labcorp Holdings Inc.A steady-state healthcare utility transitioning back to pure-play diagnostics after spinning off its clinical research business.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for LH. Not financial advice.
Price · last 12 months
Gossip
Market sentiment is currently stabilizing following the 2023 spin-off of Fortrea. Investors are debating if the leaner focus on diagnostics can drive margin expansion in a high-interest environment, while M&A chatter persists around regional lab acquisitions.
- ·Spin-off execution of Fortrea (Clinical Development)
- ·GLP-1 drug monitoring tailwinds
- ·Medicare reimbursement rate adjustments (PAMA)
- ·Strategic hospital outreach partnerships
Financial
Labcorp maintains a robust balance sheet with consistent free cash flow, though revenue growth is modest. Post-spin-off, the company is focused on capital return through dividends and share repurchases, trading at a reasonable forward P/E of roughly 14-15x.
- ·Operating Margin: ~13-15%
- ·Dividend Yield: ~1.2%
- ·Return on Equity (ROE): ~12%
- ·Net Debt/EBITDA: ~2.1x
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders sold a net $723K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·PAMA legislation potentially lowering reimbursement rates
- ·Labor cost inflation in medical technician roles
- ·Integration risks from aggressive regional lab roll-up strategy
Peer temperature
How direct competitors stack up against LH right now.
- NEUTRALDGXQuest Diagnostics
SIMILAR — Shares a near-duopoly market position but currently offers a slightly higher dividend yield and lower volatility.
See full analysis → - HOTTMOThermo Fisher Scientific
HOTTER — Offers superior diversification across life sciences tools and significantly higher historical organic growth rates.
See full analysis → - COLDNEONeoGenomics
COLDER — Focused on high-growth oncology testing but lacks LH's scale, profitability, and diversified cash flow streams.
See full analysis →
- LH+4.1%
- DGX+0.6%
- TMO+6.2%
- NEO+10.5%
Analyst price target
Consensus average of 11 analysts · median 340.00
Source: StockAnalysis.com · updated 2026-09-03
AI-generated analysis for informational purposes only. Not financial advice.